Cargando…
LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
Autores principales: | Joerger, M., Metaxas, Y., Schmitt, A., Koeberle, D., Zaman, K., Betticher, D., Mach, N., Renner, C., Mark, M.T., Petrausch, U., Caspar, C.B., Britschgi, C., Taverna, C., Zenger, F., Mingrone, W., Schulz, J., Kopp, C., Hayoz, S., Stathis, A., von Moos, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506361/ http://dx.doi.org/10.1016/j.annonc.2020.08.2321 |
Ejemplares similares
-
1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021) -
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
por: Joerger, Markus, et al.
Publicado: (2022) -
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022) -
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022) -
Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
por: Hayoz, Stefanie, et al.
Publicado: (2023)